Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1989-04-13
1990-11-27
Brown, Johnnie R.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C07H 1524
Patent
active
049736752
ABSTRACT:
N-2-chloroalkyl nitrosouredio derivatives of anthracycline-based compounds having antitumor activity are disclosed. Relative to the clinically-used drugs adriamycin and daunorubicin, substantially enhanced antitumor activity against parent murine P388 leukemia and an adriamycin-resistant P388 leukemia subline has been found for the N-2-chloroethylnitrosoureido derivatives of adriamycin, daunorubicin and epirubicin. Chemical stability has been found to be enhanced when employing the 4'-epi stereoisomeric family of these compounds.
REFERENCES:
No. 1047, Doxorubicin (DOX) Analogs Bearing Chemically Reactive Substituents, D. Farquhar, B. S. Andersson, J. E. Zuckerman and R. A. Newman, The University of Texas System Cancer Center, M. D. Anderson Hospital, Houston, Tex. 77030, Proceedings of AACR, vol. 28, Mar. 1987, p. 265.
Doxorubicin Bearing Chemically Reactive Substituents, Authors: D. Farquhar, B. S. Andersson, and R. A. Newman, The University of Texas System Cancer Center, M. D. Anderson Hospital, Houston, Tex. 77030, Investig. New Drugs, 5:115,1987, Article 9.17, p. 115.
Israel Mervyn
Seshadri Ramakrishnan
Brown Johnnie R.
Peselev Elli
University of Tennessee Research Center
LandOfFree
Hybrid nitrosoureidoanthracyclines having antitumor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid nitrosoureidoanthracyclines having antitumor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid nitrosoureidoanthracyclines having antitumor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1032464